Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big Pharma seeks long term remission x combining I/O therapy

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jan 20, 2024 9:28pm

196 Views

Post# 35837683

RE:Big Pharma seeks long term remission x combining I/O therapy

In November 2023 big pharma companies like Boehringer Ingleheim have indicated that they are seeking to achieve their strategic goals of boosting long-term remission rates among individuals with cancer, which currently only occur in 15% to 20% of patients, by combining complementary immuno-oncology platforms—such as T-cell engagers, oncolytic viruses and cancer vaccines—to expand the benefits of immunotherapy to more patients.

<< Previous

Bullboard Posts

Next >>

Online behaviour puts Canadians at risk of cyberattacks, study finds